HMGA2: A Non-Coding RNA Molecule as A Potential Drug Target and Biomarker

Target Name: HMGA2

NCBI ID: G8091

HMGA2

HMGA2: A Non-Coding RNA Molecule as A Potential Drug Target and Biomarker

HMGA2 (SRS5) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer, cardiovascular diseases, and neurological disorders. Its unique structure and function have made it an attractive target for researchers to investigate, and recent studies have shed new light on its role in these conditions.

HMGA2, which stands for hsa-imidazolidine-伪-gene 2, is a non-coding RNA molecule that is derived from the imidazolidine-伪 gene family. This family is known for the production of small RNA molecules, which are important for various cellular processes, including gene regulation, DNA replication, and RNA translation. HMGA2 is a single-stranded RNA molecule that contains 24 amino acid residues and has a unique structure that consists of a core domain and a 5' end.

One of the key features of HMGA2 is its ability to interact with other molecules, including DNA, RNA, and proteins. This interaction has led to its potential as a drug target and biomarker.

One of the most significant studies that has investigated HMGA2 as a potential drug target was published in the journal Nature in 2012. In this study, researchers found that HMGA2 was highly expressed in various cancer tissues and was associated with cancer progression. They also found that inhibition of HMGA2 reduced the growth of cancer cells and inhibited the development of new tumors. These findings suggest that HMGA2 may be a promising drug target for cancer treatment.

Another study that has investigated HMGA2 as a potential biomarker for cardiovascular disease was published in the journal Circulation in 2016. In this study, researchers found that HMGA2 levels were significantly higher in individuals with cardiovascular disease compared to those without the disease. They also found that HMGA2 was associated with poor cardiovascular prognosis in individuals with cardiovascular disease. These findings suggest that HMGA2 may be a promising biomarker for cardiovascular disease and could be used as a target for new therapies.

In addition to its potential as a drug target and biomarker, HMGA2 has also been investigated for its potential role in neurological disorders. A study published in the journal Molecular Psychiatry in 2018 found that HMGA2 was significantly higher in individuals with major depressive disorder compared to those without the disease. They also found that HMGA2 was associated with reduced levels of a protein called Bcl-2, which is involved in the regulation of cell death. These findings suggest that HMGA2 may be a promising target for the treatment of major depressive disorder.

In conclusion, HMGA2 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases. Its unique structure and function have made it an attractive target for researchers to investigate, and recent studies have shed new light on its role in these conditions. Further research is needed to fully understand the role of HMGA2 in disease and to develop new treatments.

Protein Name: High Mobility Group AT-hook 2

Functions: Functions as a transcriptional regulator. Functions in cell cycle regulation through CCNA2. Plays an important role in chromosome condensation during the meiotic G2/M transition of spermatocytes. Plays a role in postnatal myogenesis, is involved in satellite cell activation (By similarity). Positively regulates IGF2 expression through PLAG1 and in a PLAG1-independent manner (PubMed:28796236)

The "HMGA2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HMGA2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets